Other headlinesPET radiotracer developers expand suppo
InSight revenues fall
Revenues decreased 17% for InSight Health in the fourth quarter, adding to an already down year for the provider of outpatient and mobile imaging services. For fiscal 2009 ended June 30, revenues decreased 13% from approximately $265 million in the previous fiscal year to $229 million. In the fourth quarter, revenues from fixed operations decreased approximately 21% to approximately $32.3 million, principally due to declines at imaging centers. Revenues from mobile operations decreased approximately 12% to $21.3 million, primarily due to reductions in reimbursement from its customers and a decline in the number of customers served. For the fiscal year, revenues for fixed operations decreased 17% to $139 million, while those for mobile operations decreased 6% to $90 million.
PET radiotracer developers expand support
Aposense and Ion Beam Applications have agreed to share the cost of phase III clinical tests aimed at commercializing a PET radiotracer that promises to show after a few days whether a chemo regimen is helping cancer patients. The radiotracer, dubbed Aposense 18F–ML-10, is designed to visualize apoptosis, a fundamental biological process of controlled cell death. Phase II trials are currently underway. Phase III studies, which the companies hope will pave the way ultimately to FDA approval, will not begin until at least 2011. The new agreement between Aposense and Ion Beam Applications expands their collaboration, struck last year, to develop and supply the radiotracer to multiple clinical trial sites in the U.S., and to develop the processes necessary for commercial scale distribution.It also details their collaboration in marketing the radiotracer, following its regulatory approval.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.